Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds

Elanco Animal Health Inc

2022-Q3 EPS reported -$0.05 revenue$3,430,000,000

Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.
Reported EPS $(0.10); adjusted EPS $0.20 (up 5% YoY); adjusted EBITDA $205M (19.9% margin, +120bps).
FY 2022 revenue guidance lowered to $4,385-4,430M (from $4,465-4,550M); adjusted EPS cut to $1.01-1.07 from $1.06-1.13.
Net leverage ratio 5.2x; $170M gross debt reduction in Q3; cash flow from ops $189M vs $89M YoY.
Pipeline: FDA submission for broad-spectrum parasiticide; SGLT-2 feline diabetes drug and parvovirus mAb expected approvals by early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2022 results: revenue $1,028 million, net income Reported Net Loss of $49 million, EPS Reported EPS of $(0.10). Guidance lowered.

Period: the fiscal quarter ended September 30, 2022
Revenue: $1,028 million
Net income: Reported Net Loss of $49 million
EPS: Reported EPS of $(0.10)
Guidance: lowered
Result: reported results

Exact text from the filing

Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2022 Results • Third Quarter 2022 Financial Results ◦ Revenue of $1,028 million ◦ Reported Net Loss of $49 million, Adjusted Net Income of $96 million ◦ Adjusted EBITDA of $205 million or 19.9% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.20 ◦

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-22-115672

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.